AU2001264011B2 - Use of biguanide derivatives for making a medicine having a wound healing effect - Google Patents
Use of biguanide derivatives for making a medicine having a wound healing effect Download PDFInfo
- Publication number
- AU2001264011B2 AU2001264011B2 AU2001264011A AU2001264011A AU2001264011B2 AU 2001264011 B2 AU2001264011 B2 AU 2001264011B2 AU 2001264011 A AU2001264011 A AU 2001264011A AU 2001264011 A AU2001264011 A AU 2001264011A AU 2001264011 B2 AU2001264011 B2 AU 2001264011B2
- Authority
- AU
- Australia
- Prior art keywords
- group
- alkyl group
- metformin
- represent
- biguanide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000004283 biguanides Chemical class 0.000 title claims description 21
- 230000000694 effects Effects 0.000 title description 9
- 239000003814 drug Substances 0.000 title 1
- 230000029663 wound healing Effects 0.000 title 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 33
- 229960003105 metformin Drugs 0.000 claims description 33
- 208000027418 Wounds and injury Diseases 0.000 claims description 28
- 206010052428 Wound Diseases 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229940126601 medicinal product Drugs 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 17
- 239000002674 ointment Substances 0.000 claims description 16
- 230000009471 action Effects 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000000699 topical effect Effects 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 150000003512 tertiary amines Chemical group 0.000 claims description 5
- 150000001412 amines Chemical group 0.000 claims description 4
- 125000006701 (C1-C7) alkyl group Chemical group 0.000 claims description 3
- 230000000052 comparative effect Effects 0.000 claims description 3
- 150000003840 hydrochlorides Chemical class 0.000 claims description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- -1 for example Chemical group 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical class NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000007431 microscopic evaluation Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010065452 Angiodermatitis Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- XYGMEFJSKQEBTO-KUJXMBTLSA-N Clostebol acetate Chemical compound C1CC2=C(Cl)C(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)C)[C@@]1(C)CC2 XYGMEFJSKQEBTO-KUJXMBTLSA-N 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 208000035901 Ischaemic ulcer Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000005230 Leg Ulcer Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 1
- 229960003243 phenformin Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0006798A FR2809310B1 (fr) | 2000-05-26 | 2000-05-26 | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
| FR00/06798 | 2000-05-26 | ||
| PCT/FR2001/001598 WO2001091696A2 (fr) | 2000-05-26 | 2001-05-23 | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001264011A1 AU2001264011A1 (en) | 2002-02-28 |
| AU2001264011B2 true AU2001264011B2 (en) | 2005-09-15 |
Family
ID=8850685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001264011A Expired AU2001264011B2 (en) | 2000-05-26 | 2001-05-23 | Use of biguanide derivatives for making a medicine having a wound healing effect |
| AU6401101A Pending AU6401101A (en) | 2000-05-26 | 2001-05-23 | Use of biguanide derivatives for making a medicine having a wound healing effect |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU6401101A Pending AU6401101A (en) | 2000-05-26 | 2001-05-23 | Use of biguanide derivatives for making a medicine having a wound healing effect |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7199159B2 (enExample) |
| EP (1) | EP1283708B1 (enExample) |
| JP (1) | JP4987209B2 (enExample) |
| KR (1) | KR20030029050A (enExample) |
| CN (1) | CN100420439C (enExample) |
| AR (1) | AR032617A1 (enExample) |
| AT (1) | ATE300942T1 (enExample) |
| AU (2) | AU2001264011B2 (enExample) |
| BG (1) | BG65847B1 (enExample) |
| BR (1) | BRPI0111142C1 (enExample) |
| CA (1) | CA2410025C (enExample) |
| DE (1) | DE60112431T2 (enExample) |
| DK (1) | DK1283708T3 (enExample) |
| EC (1) | ECSP024359A (enExample) |
| EE (1) | EE05393B1 (enExample) |
| ES (1) | ES2244625T3 (enExample) |
| FR (1) | FR2809310B1 (enExample) |
| HU (1) | HU229205B1 (enExample) |
| MX (1) | MXPA02011622A (enExample) |
| MY (1) | MY137468A (enExample) |
| NO (1) | NO20025635L (enExample) |
| PT (1) | PT1283708E (enExample) |
| SK (1) | SK287249B6 (enExample) |
| UA (1) | UA76415C2 (enExample) |
| WO (1) | WO2001091696A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2858232B1 (fr) * | 2003-07-29 | 2006-03-03 | Pierre Potier | Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb |
| DE102004022645A1 (de) * | 2004-05-07 | 2005-12-15 | Resorba Wundversorgung Gmbh & Co. Kg | Bioresorbierbares Material auf Kollagen-Basis |
| JP4877456B2 (ja) * | 2005-04-14 | 2012-02-15 | 株式会社 メドレックス | ビグアナイド系薬剤を含有するゼリー製剤 |
| WO2008093984A1 (en) | 2007-01-29 | 2008-08-07 | Hanall Pharmaceutical Company. Ltd | N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same |
| US20100055142A1 (en) * | 2008-08-28 | 2010-03-04 | Tyco Healthcare Group Lp | Carrier Neutralization/Modification in Antimicrobial Compositions, Articles and Methods |
| KR101274981B1 (ko) | 2010-01-06 | 2013-06-18 | 한올바이오파마주식회사 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| US10279007B2 (en) | 2010-11-15 | 2019-05-07 | Oxygenetix Institute, Inc. | Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs |
| DE212011100215U1 (de) | 2011-07-22 | 2014-03-05 | Karel Paul Bouter | Ernährungsprodukt, umfassend ein Biguanid |
| KR101486865B1 (ko) | 2011-08-08 | 2015-01-30 | 한올바이오파마주식회사 | Ｎ1-고리아민-ｎ5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| WO2013022280A2 (en) * | 2011-08-08 | 2013-02-14 | Hanall Biopharma Co., Ltd. | N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
| EP2742019B1 (en) * | 2011-08-08 | 2021-03-03 | Immunomet Therapeutics Inc. | N1-cyclic amine-n5-substituted phenyl biguanide derivatives and pharmaceutical composition comprising the same |
| JP6487031B2 (ja) * | 2014-04-17 | 2019-03-20 | イミューノメット セラピューティクス インコーポレイテッド | グアニジン化合物、及びその用途 |
| CN104262205B (zh) * | 2014-09-02 | 2017-04-12 | 浙江工业大学 | N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用 |
| KR102216701B1 (ko) | 2014-11-20 | 2021-02-18 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
| FR3035787B1 (fr) | 2015-05-07 | 2018-08-24 | L'oreal | Procede de traitement des matieres keratiniques a partir de derives de c-glycosides amides, acides ou ester, et la composition cosmetique les contenant |
| FR3053892A1 (fr) | 2016-07-12 | 2018-01-19 | Urgo Recherche Innovation Et Developpement | Pansement permettant la liberation controlee et prolongee de la metformine |
| CN106822075A (zh) * | 2017-03-31 | 2017-06-13 | 浙江萧山医院 | 二甲双胍在促进伤口愈合中的应用 |
| FR3068974B1 (fr) | 2017-07-12 | 2019-08-02 | Urgo Recherche Innovation Et Developpement | Pansement permettant la liberation controlee et prolongee d'actif |
| FR3088542B1 (fr) | 2018-11-21 | 2021-03-19 | Waterdiam France Sas | Composition cicatrisante comprenant une eau électrolysée |
| CN110179776B (zh) * | 2019-05-31 | 2022-09-06 | 宁夏医科大学 | 二甲双胍的新用途与二甲双胍组合物及组合物的制备方法和应用 |
| CN112494469A (zh) * | 2020-07-30 | 2021-03-16 | 吴学雷 | 二甲双胍在制备预防和/或治疗瘢痕的药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1560212A1 (ru) * | 1988-11-10 | 1990-04-30 | Киевский Медицинский Институт Им.Акад.А.А.Богомольца | Способ лечени сифилиса |
| EP0535446A1 (en) * | 1991-09-30 | 1993-04-07 | BONISCONTRO E GAZZONE S.r.l. | Pharmaceutical compositions for topical use containing a chelating agent, a tocopheral and an antimicrobial agent |
| CN1197643A (zh) * | 1997-04-30 | 1998-11-04 | 谢瑞钢 | 一种创伤油膏 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB852584A (en) | 1956-05-31 | 1960-10-26 | Us Vitamin Corp | Biguanide compositions |
| US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
| US3098008A (en) * | 1960-10-05 | 1963-07-16 | Us Vitamin Pharm Corp | Method for treatment of dermatological disorders |
| US3174901A (en) | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| US3468898A (en) | 1966-05-26 | 1969-09-23 | Sterling Drug Inc | Bridged bis-biguanides and bis-guanidines |
| US3996232A (en) * | 1970-11-23 | 1976-12-07 | William H. Rorer, Inc. | 1,5-Disubstituted biguanides |
| GB1351025A (en) | 1971-08-20 | 1974-04-24 | Aron Md Samuel J | Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them |
| US3852353A (en) | 1972-12-12 | 1974-12-03 | C Heaphy | Oral hypoglycemic aminophenylsulfonyl-hydrocarbylbiguanides |
| US3929999A (en) | 1972-12-12 | 1975-12-30 | Clifford John Heaphy | Oral hypoglycemic method |
| DE2401450A1 (de) * | 1973-01-16 | 1974-07-18 | John James Voorhees | Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen |
| US4211770A (en) * | 1973-01-16 | 1980-07-08 | The Upjohn Company | Treatment of psoriasis intralesionally with N6 -2'-O-dibutyryl cyclic AMP |
| CH602612A5 (enExample) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
| FR2320735A1 (fr) * | 1975-08-12 | 1977-03-11 | Dabis Georges | Composition anti-cellulite |
| US4163800A (en) * | 1977-08-17 | 1979-08-07 | The Procter & Gamble Company | Topical composition and treatment of skin lesions therewith |
| NZ207147A (en) | 1983-02-28 | 1987-08-31 | Johnson & Johnson Prod Inc | Adhesive bandage containing medicinal substance: pad and base prepared from bulky, non-woven material |
| FR2552305B1 (fr) * | 1983-09-22 | 1985-12-20 | Salkin Andre | Composition a pouvoir bactericide eleve contenant un biguanide et une pyrimidine |
| FR2585572B3 (fr) | 1985-07-31 | 1987-12-31 | Hugelin Andre | Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse |
| FR2611500B1 (fr) * | 1987-03-06 | 1990-05-04 | Lipha | Emploi de derives du biguanide dans la preparation de medicaments |
| AU1834188A (en) | 1987-06-29 | 1989-01-05 | Kendall Company, The | Novel medicated dressings |
| US5246708A (en) | 1987-10-28 | 1993-09-21 | Pro-Neuron, Inc. | Methods for promoting wound healing with deoxyribonucleosides |
| IT1241994B (it) | 1990-08-30 | 1994-02-02 | Idi Farmaceutici | Composizione farmaceutica ad effetto cicatrizzante. |
| IL97771A (en) * | 1991-04-04 | 1996-12-05 | Sion Narrow Weaving | Dry polymeric material having antimicrobial activity |
| IT1256111B (it) * | 1992-11-23 | 1995-11-28 | Lifegroup Spa | Sali dell'acido traumatico ad attivita' cicatrizzante ed antibatterica |
| JP3493692B2 (ja) | 1993-09-09 | 2004-02-03 | 三菱マテリアル株式会社 | ビスビグアナイド系化合物およびそれを含む殺菌剤 |
| DE19503336C2 (de) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5747527A (en) * | 1995-06-06 | 1998-05-05 | Shaman Pharmaceuticals, Inc. | Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes |
| US5668084A (en) | 1995-08-01 | 1997-09-16 | Zeneca Inc. | Polyhexamethylene biguanide and surfactant composition and method for preventing waterline residue |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| US5837255A (en) * | 1996-12-10 | 1998-11-17 | Shaman Pharmaceuticals, Inc. | Method of reducing blood glucose by administering Harunganin or Vismin |
| US5741926A (en) * | 1997-02-12 | 1998-04-21 | Shaman Pharmaceuticals, Inc. | Aniline derivatives having antihyperglycemic activity |
| US5811078A (en) * | 1997-03-14 | 1998-09-22 | Adolor Corporation | Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith |
| JP3054758B2 (ja) * | 1997-03-27 | 2000-06-19 | 小林製薬株式会社 | 外傷用組成物 |
| ES2216335T3 (es) * | 1997-12-08 | 2004-10-16 | Bristol-Myers Squibb Company | Nuevas sales de metformina y procedimiento. |
| CN1204890C (zh) * | 1997-12-22 | 2005-06-08 | 欧罗赛铁克股份有限公司 | 防止阿片样物质滥用的方法 |
| ATE292956T1 (de) * | 1998-07-24 | 2005-04-15 | Seo Hong Yoo | Klare wässrige lösungen enthaltend gallensäuren |
| AU1969500A (en) | 1998-12-05 | 2000-06-26 | Fresenius Kabi Deutschland Gmbh | Use of poly (hexamethylene) biguanide for producing an agent for promoting the healing of uninfected wounds |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| CO5200844A1 (es) | 1999-09-17 | 2002-09-27 | Novartis Ag | Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes |
| PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
| US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
| AU3982601A (en) * | 2000-02-23 | 2001-09-03 | Orentreich Foundation For The | Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus |
| ES2218338T3 (es) * | 2000-04-13 | 2004-11-16 | Pfizer Products Inc. | Efecto sinergico de gliburida y milrinona. |
-
2000
- 2000-05-26 FR FR0006798A patent/FR2809310B1/fr not_active Expired - Lifetime
-
2001
- 2001-05-23 ES ES01938318T patent/ES2244625T3/es not_active Expired - Lifetime
- 2001-05-23 PT PT01938318T patent/PT1283708E/pt unknown
- 2001-05-23 CA CA2410025A patent/CA2410025C/fr not_active Expired - Lifetime
- 2001-05-23 EP EP01938318A patent/EP1283708B1/fr not_active Expired - Lifetime
- 2001-05-23 EE EEP200200657A patent/EE05393B1/xx not_active IP Right Cessation
- 2001-05-23 DE DE60112431T patent/DE60112431T2/de not_active Expired - Lifetime
- 2001-05-23 DK DK01938318T patent/DK1283708T3/da active
- 2001-05-23 SK SK1658-2002A patent/SK287249B6/sk not_active IP Right Cessation
- 2001-05-23 MX MXPA02011622A patent/MXPA02011622A/es active IP Right Grant
- 2001-05-23 AT AT01938318T patent/ATE300942T1/de active
- 2001-05-23 UA UA2002097477A patent/UA76415C2/uk unknown
- 2001-05-23 AU AU2001264011A patent/AU2001264011B2/en not_active Expired
- 2001-05-23 JP JP2001587712A patent/JP4987209B2/ja not_active Expired - Lifetime
- 2001-05-23 KR KR1020027016052A patent/KR20030029050A/ko not_active Ceased
- 2001-05-23 WO PCT/FR2001/001598 patent/WO2001091696A2/fr not_active Ceased
- 2001-05-23 BR BRPI0111142A patent/BRPI0111142C1/pt not_active IP Right Cessation
- 2001-05-23 HU HU0302038A patent/HU229205B1/hu not_active IP Right Cessation
- 2001-05-23 US US10/297,003 patent/US7199159B2/en not_active Expired - Lifetime
- 2001-05-23 AU AU6401101A patent/AU6401101A/xx active Pending
- 2001-05-23 CN CNB018114032A patent/CN100420439C/zh not_active Expired - Lifetime
- 2001-05-24 AR ARP010102484A patent/AR032617A1/es unknown
- 2001-05-24 MY MYPI20012487A patent/MY137468A/en unknown
-
2002
- 2002-11-21 BG BG107304A patent/BG65847B1/bg unknown
- 2002-11-22 NO NO20025635A patent/NO20025635L/no not_active Application Discontinuation
- 2002-11-22 EC EC2002004359A patent/ECSP024359A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1560212A1 (ru) * | 1988-11-10 | 1990-04-30 | Киевский Медицинский Институт Им.Акад.А.А.Богомольца | Способ лечени сифилиса |
| EP0535446A1 (en) * | 1991-09-30 | 1993-04-07 | BONISCONTRO E GAZZONE S.r.l. | Pharmaceutical compositions for topical use containing a chelating agent, a tocopheral and an antimicrobial agent |
| CN1197643A (zh) * | 1997-04-30 | 1998-11-04 | 谢瑞钢 | 一种创伤油膏 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001264011B2 (en) | Use of biguanide derivatives for making a medicine having a wound healing effect | |
| US10881640B2 (en) | Topical pharmaceutical compositions for treatment of pilonidal sinus wounds | |
| JP2018525348A (ja) | 皮膚の炎症を抑制するイガイ接着タンパク質製品及びその適用 | |
| WO2008094061A1 (en) | Pharmaceutical and cosmetic compositions for accelerated healing of wounds and other surface damages | |
| JP2013060455A (ja) | ハチ毒を有効成分とする組成物 | |
| KR20200112012A (ko) | (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물 | |
| EP1397124B1 (fr) | Utilisation d'agents antidiabetiques pour fabriquer un medicament ayant un effet cicatrisant | |
| CN117427078A (zh) | 化合物g194-0712在制备促进皮肤创面愈合的药物中的用途 | |
| US20130045269A1 (en) | Formulations and methods for wound treatment | |
| EP1517691B1 (de) | Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben | |
| US20250367224A1 (en) | Galactose and fucose monosaccharides for re-epithelialization and treating lesions | |
| US6395779B1 (en) | Method of treatment using peroxidized lipids | |
| US10905729B1 (en) | Formulations and methods for wound treatment | |
| KR102224110B1 (ko) | Abh 항원의 발현을 조절하는 물질을 포함하는 모공 축소용 조성물 | |
| KR20250114272A (ko) | 튜불린 저해제를 포함하는 병용요법을 이용한 피부 질환 예방 또는 치료용 조성물 | |
| WO2025252795A1 (en) | Galactose and fucose monosaccharides for re-epithelialization and treating lesions | |
| CN117442610A (zh) | 化合物8519-0065在制备促进皮肤创面愈合的药物中的用途 | |
| CN119798373A (zh) | 一种促进伤口愈合的药物组合物及其制备方法 | |
| CN117659124A (zh) | 一类促进组织修复的新多肽及其应用 | |
| CN111228465A (zh) | 一种治疗痤疮的药物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |